### **EPFL** New plasma-based sterilization methods

### PI : I. Furno Co-PI: A. C. Oates



SV Infrastructures



1

Swiss Plasma Center

# **EPFL** The goal of this project

Develop a prototype device for **sterilization** and **decontamination** of solid surfaces and liquids based on a novel **plasma-based** technology

- ✓ energy efficient
- $\checkmark$  no storage of harmful chemicals
- $\checkmark$  no long-lived toxic residues
- ✓ low cost

Alternative to standard autoclaving Reduce environmental footprint (energy/CO<sub>2</sub>/water) Open new fields of application To be demonstrated by 2025 in the EPFL SV-IN facility


#### Why? EPFL |

Pros

Sterilization/decontamination essential in are research laboratories and clinical facilities

Autoclaves are the workhorse (pressurized steam)

At EPFL 30 autoclaves in SV-IN facility



	600110108/	
$\checkmark$	Fast sterilization	
	(~Ih for 6-Log	
	reduction)	

**Established** 

technology


industrial

No heat/pressure/moisturesensitive materials

(developing countries?)




### **EPFL** How ? Plasma-based sterilization technology




Plasma source: Dielectric barrier discharge (DBD)

### **EPFL** How ? Plasma-based sterilization technology



### **EPFL** How ? Plasma-based sterilization technology




### **EPFL** Plasma-based sterilization has many advantages

- ✓ atmospheric plasmas are a fast-sterilizing agent
- plasma produced from ambient air when needed
- ✓ energy efficient
- ✓ usable for heat/pressure/H₂O-sensitive materials
- no need for complex pumping system
- ✓ no need for harmful chemicals
- ✓ no long-lived toxic residues



### ... and one disadvantage: it needs development!

## **EPFL** This requires interdisciplinarity of partners



### Swiss Plasma Center

6

Aleksandra LAVRIKOVA, Rita AGUS, Fabio AVINO, Ivo FURNO

> Segmentation Timing and Dynamics Laboratory Vivianne PADRUN, Laurence WINKEL, Andrew C. OATES

## **EPFL** First 8 months: decontamination of liquids

Contaminated Liquids (BSL2)

Gram positive bacteria Bacillus thuringiensis: UPLEM; Micrococcus luteus Gram negative bacteria E. coli: 90% de labo SV, Pseudomonas putida Fungi Neurospora crassa: milieu Agar 1,5-2% (solid) Yeast Saccharomyces cerevisiae: milieu YPD Virus + cell lines to test plasma treatment efficacy Viral vector AAV with reporter gene like GFP : PBS Buffer. Cell line 293T: milieu DMEM + 10% Fœtal Bovine Serum.



# **EPFL** First 8 months: decontamination of liquids



Gram positive bacteria Bacillus thuringiensis: UPLEM; Micrococcus luteus Gram Negative bacteria E. coli: 90% de labo SV, Pseudomonas putida Fungi Neurospora crassa: milieu Agar 1,5-2% (solid) Yeast Saccharomyces cerevisiae: milieu YPD Virus + cell lines to test plasma treatment efficacy Viral vector AAV with reporter gene like GFP : PBS Buffer. Cell line 293T: milieu DMEM + 10% Fœtal Bovine Serum.

Collected liquid waste



In-situ treatment (no transportation)


### Inactivated waste




Off-site destruction




## **EPFL** SDBDs sterilize with low energy efficiency





# **EPFL** We are on track with the project timeline





Can we develop "greener" sterilization methods?

A prototype device for sterilization and decontamination based on a novel plasma technology to be demonstrated by 2025 at EPFL

Broad impact at EPFL and outside (labs, hospitals, clinical centers,...) covering a global multi-Bn market

Attract private funding to industrialize the technology

YES!